David Holland's most recent trade in Kiora Pharmaceuticals Inc was a trade of 20,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on April 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kiora Pharmaceuticals Inc | David A. Hollander | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Revance Therapeutics Inc | David A. Hollander | CMO & Global Therapeutics Lead | Sale of securities on an exchange or to another person at price $ 4.17 per share. | 18 Nov 2024 | 3,908 | 104,945 (0%) | 0% | 4.2 | 16,296 | Common Stock |
| Kiora Pharmaceuticals Inc | David A. Hollander | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 1,778 | 1,778 | - | - | Stock Option (right to buy) | |
| Alimera Sciences Inc. | David Holland | Chief Marketing Officer & SVP | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2023 | 68,000 | 108,880 (2%) | 1% | 0 | Common Stock | |
| Kiora Pharmaceuticals Inc | David Hollander | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 8,000 | 8,000 | - | - | Stock Option (right to buy) | |
| Alimera Sciences Inc. | David Holland | Chief Marketing Officer & SVP | Grant, award, or other acquisition of securities at price $ 4.44 per share. | 31 Oct 2022 | 500 | 40,880 (0%) | 0% | 4.4 | 2,219 | Common Stock |
| Alimera Sciences Inc. | David Holland | Chief Marketing Officer & SVP | Grant, award, or other acquisition of securities at price $ 3.76 per share. | 29 Apr 2022 | 500 | 40,380 (0%) | 0% | 3.8 | 1,879 | Common Stock |
| Kiora Pharmaceuticals Inc | David Hollander | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Kiora Pharmaceuticals Inc | David Hollander | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 4,000 | 4,000 | - | - | Stock Option (right to buy) | |
| Alimera Sciences Inc. | David Holland | Chief Marketing Officer & SVP | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2022 | 26,250 | 26,250 | - | - | Employee Stock Option (Right to Buy) | |
| Alimera Sciences Inc. | David Holland | Chief Marketing Officer & SVP | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2022 | 8,750 | 39,880 (0%) | 0% | 0 | Common Stock | |
| Alimera Sciences Inc. | David Holland | Chief Marketing Officer & SVP | Purchase of securities on an exchange or from another person at price $ 4.08 per share. | 03 Nov 2021 | 5,000 | 31,130 (0%) | 0% | 4.1 | 20,392 | Common Stock |
| Alimera Sciences Inc. | David Holland | Chief Marketing Officer & SVP | Grant, award, or other acquisition of securities at price $ 3.76 per share. | 29 Oct 2021 | 500 | 26,130 (0%) | 0% | 3.8 | 1,879 | Common Stock |
| Alimera Sciences Inc. | David Holland | Chief Marketing Officer & SVP | Grant, award, or other acquisition of securities at price $ 3.56 per share. | 30 Apr 2021 | 500 | 25,630 (0%) | 0% | 3.6 | 1,781 | Common Stock |
| Alimera Sciences Inc. | David Holland | Chief Operating Officer & SVP | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.41 per share. | 08 Mar 2021 | 1,935 | 25,130 (0%) | 0% | 7.4 | 14,348 | Common Stock |
| Alimera Sciences Inc. | David Holland | Chief Marketing Officer & SVP | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2021 | 16,875 | 16,875 | - | - | Employee Stock Option (Right to Buy) | |
| Alimera Sciences Inc. | David Holland | Chief Marketing Officer & SVP | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2021 | 5,625 | 27,065 (0%) | 0% | 0 | Common Stock | |
| Alimera Sciences Inc. | David Holland | Chief Marketing Officer & SVP | Grant, award, or other acquisition of securities at price $ 3.56 per share. | 30 Oct 2020 | 500 | 21,440 (0%) | 0% | 3.6 | 1,781 | Common Stock |